As PET scans fall short, blood-based circulating tumor DNA testing shows promise in monitoring large B-cell lymphoma ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced Medicare coverage of its ultrasensitive NeXT Personal® test for surveillance of cancer recurrence ...

Clinicians have long relied on clinical risk factors, imaging, and pathology to guide cancer surveillance and adjuvant treatment. However, even after curative-intent surgery and definitive therapy, ...

– Helps to detect circulating tumor DNA (ctDNA) as a biomarker in clinical research and clinical trials for solid tumor malignancies – – May provide real-time data on therapy response, support patient ...

CEO Chad Robins highlighted a strong year for Adaptive Biotechnologies, with MRD revenue increasing by 42% year-over-year. Key drivers included a higher gapfill rate of $2,007 for the clonoSEQ test ...

Detailed price information for Telo Genomics Corp (TELO-X) from The Globe and Mail including charting and trades.

Adela's tissue-agnostic MRD test has been clinically validated to predict and surveil for recurrence in patients with head & neck cancer, regardless of HPV status The test identified recurrences in ...

Coverage marks a pivotal step in expanding access to ultra-sensitive MRD detection for breast cancer patients U.S. Medicare coverage decision reflects published, peer-reviewed clinical data ...

(RTTNews) - Myriad Genetics, Inc. (MYGN) announced new interim data from the MONSTAR-SCREEN-3 study, showcasing the high sensitivity and pan-cancer applicability of its Precise Minimal Residual ...

MRD signifies remaining cancer cells post-treatment, with interpretations varying by cancer type. MRD testing methods include flow cytometry and genomic tests, detecting residual cancer cells.

A looming revolution in oncology could help the 18 million cancer survivors in the U.S. and bolster biotech stocks like Guardant Health, Natera and Exact Sciences. And all it takes is a little blood.